This is the first approved drug for treating agitation in patients with Alzheimer’s disease, the company said in a statement.

Otsuka and Lundbeck won approval Friday for Abilify Asimtufii, a long-acting injectable that provides two months of symptom relief in patients with schizophrenia or bipolar I disorder.

Shares in Lundbeck rose 9% on Tuesday after the Danish drug maker posted fourth-quarter sales above forecasts and projected a more rapid increase in its profit margin in the coming years than analysts had expected.

Copenhagen-based Lundbeck revealed Wednesday that its migraine drug Vyepti (eptinezumab) failed to demonstrate statistical superiority over placebo at reducing the number of monthly migraine days.